Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar as planned following six months as acting chief executive officer. Dr. Pedder will continue to serve as a director.
Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2013.
Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Wed Mar 19, 7:54AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full year 2013 financial results, provide an update on each of its development programs and discuss expectations for fiscal 2014 on Tuesday, March 25 at 5:00 PM ET.
Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
GlobeNewswire - Tue Mar 04, 7:01AM CST
Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma.